Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy

Journal of the Formosan Medical Association

Volumn 107, Issue 6, 2008, Pages 454-462

  Chang, Shu Chuan ^a   Ko, Wang Sheng ^b   Wu, Shun Sheng ^c   Peng, Cheng Yuan ^d   Yang, Sheng Shun ^a,e,f  

^a CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b KUANG TIEN GENERAL HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Chronic hepatitis C; Quality of life; Social support

Indexed keywords

INTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DISABILITY; DRUG COST; FEMALE; FINANCIAL MANAGEMENT; HEALTH SURVEY; HEPATITIS C; HEPATITIS QUALITY OF LIFE QUESTIONNAIRE; HUMAN; INVENTORY OF SOCIALLY SUPPORTIVE BEHAVIORS; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; QUALITY OF LIFE; QUESTIONNAIRE; REGRESSION ANALYSIS; SOCIAL STATUS; SOCIAL SUPPORT; TAIWAN; TREATMENT DURATION;

EID: 48049089814     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(08)60153-9     Document Type: Article

References (29)

1. Sheu JC, Wang JT, Wang TH, et al. Prevalence of hepatitis C virus infection in a community in Taiwan. Detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993;17:192-8.
2. Lu SN, Chue PY, Chen HC, et al. Different viral etiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol 1997;12:547-50.
3. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:S21-9.
4. Sharara AI, Hunt CM, Hamilton JD. Medical progress in hepatitis C. Ann Intern Med 1996;125:658-68.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.
7. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44.
8. Hunt CM, Dominitz JA, Bute BP, et al. Effect of interferon-α treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997;42:2482-6.
9. Yu ML, Dai CY, Lin ZY, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006;26:73-81.
10. Davis GL, Balart LA, Schiff ER, et al. Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther 1994;16:334-43.
11. Bayliss MS, Gandek B, Bungay KM, et al. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998; 7:39-55.
12. Ware JE Jr, Bayliss S, Mannocchia M, et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology 1999;30:550-5.
13. Heitkemper M, Jarrett M, Kurashige EM, et al. Chronic hepatitis C implications for health-related quality of life. Gastroenterol Nursing 2000;24:170-7.
14. Hopwood M, Treloar C. The experience of interferon-based treatments for hepatitis C infection. Qual Health Res 2005;15:635-46.
15. Dieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44:104-12.
16. Turner J, Noh S. Physical disability and depression: a longitudinal analysis. J Health Social Behav 1998;29:23-37.
17. Hutchison C. Social support: factors to consider when designing studies that measure social support. J Adv Nursing Res 1999;29:1520-6.
18. Friedland J, Renwick R, McColl M. Coping and social support as determinants of quality of life in HIV/AIDS. AIDS Care 1996;8:15-32.
19. Bastardo YM, Kimberlin CL. Relationship between quality of life, social support and disease-related factors in HIV-infected persons in Venezuela. AIDS Care 2000;12: 673-84.
20. Jessop AB, Cohen C, Burke MM, et al. Hepatitis support groups: meeting the information and support needs of hepatitis patients. Gastroenterol Nursing 2004;27:163-9.
21. Yu HS, Chung HH. Quality of life for patients with hepatocellular carcinoma receiving transcatheter arterial chemoembolization. New Taipei J Nursing 1999;1:21-9. [In Chinese]
22. Wu JJ, Weng LC, Chang CF, et al. A preliminary study of quality of life in post liver transplantation patients. Chang Gung Nursing 2002;13:193-204. [In Chinese]
23. Huang LC, Liu HE, Li CY, et al. Quality of life and the associated factors among Tayal aboriginal patients with liver cirrhosis in I-Lan. Fu Jen J Med 2004;2:27-36. [In Chinese]
24. Bayliss MS. Methods in outcomes research in hepatology: definitions and domains of quality of life. Hepatology 1999;29(Suppl 6):S3-6.
25. Barrera M, Sandler IN, Ramsay TB. Preliminary development of a scale of social support: studies on college students. Am J Com Psy 1981;9:413-45.
26. Foster GR. Hepatitis C virus infection: quality of life and side effects of treatment. J Hepatol 1999;31:250-4.
27. Kang SC, Hwang SJ, Lee SH, et al. Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol 2005;1:7494-8.
28. Chen HM. Prescription Adherence and Its Related Factors in Chronic Hepatitis C patients Receiving Regimen of Interferon and Ribavirin Treatment - A Longitudinal Study. Unpublished master's thesis, National Taiwan University, Taipei, Taiwan, 2006.
29. Miller ER, Hiller JE, Shaw DR. Quality of life in HCV-infection: lack of association with ALT levels. Aust N Z J Public Health 2001;25:355-61.